Pharma sto_老虎社区_美港股上老虎

2021-12-28

Pharma stocks are riding on roller coasters daily -_-"

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":696611114,"tweetId":"696611114","gmtCreate":1640679854232,"gmtModify":1640679854347,"author":{"id":3553874814538487,"idStr":"3553874814538487","authorId":3553874814538487,"authorIdStr":"3553874814538487","name":"JoanneTan","avatar":"https://static.tigerbbs.com/ec134af3cd0974621433a232f7c6ec60","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":6,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Pharma stocks are riding on roller coasters daily -_-\"</p></body></html>","htmlText":"<html><head></head><body><p>Pharma stocks are riding on roller coasters daily -_-\"</p></body></html>","text":"Pharma stocks are riding on roller coasters daily -_-\"","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/696611114","repostId":1187889461,"repostType":4,"repost":{"id":"1187889461","pubTimestamp":1640657510,"share":"https://www.laohu8.com/m/news/1187889461?lang=&edition=full","pubTime":"2021-12-28 10:11","market":"us","language":"en","title":"Why Novavax Stock Is Sinking Today","url":"https://stock-news.laohu8.com/highlight/detail?id=1187889461","media":"Motley Fool","summary":"What happened\nShares of Novavax(NASDAQ:NVAX)were sinking 9.6% as of 11:47 a.m. ET on Monday. The com","content":"<p>What happened</p>\n<p>Shares of&nbsp;<b>Novavax</b>(NASDAQ:NVAX)were sinking 9.6% as of 11:47 a.m. ET on Monday. The company didn't announce any new developments. So what's behind the big decline?</p>\n<p>Other&nbsp;vaccine stocks&nbsp;aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.</p>\n<p>Instead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.</p>\n<p>CEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"</p>\n<p>So what</p>\n<p>Yet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.</p>\n<p>But it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.</p>\n<p>Now what</p>\n<p>Investors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Novavax Stock Is Sinking Today</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Novavax Stock Is Sinking Today\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-28 10:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/12/27/why-novavax-stock-is-sinking-today/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>What happened\nShares of Novavax(NASDAQ:NVAX)were sinking 9.6% as of 11:47 a.m. ET on Monday. The company didn't announce any new developments. So what's behind the big decline?\nOther vaccine stocks ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/12/27/why-novavax-stock-is-sinking-today/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://www.fool.com/investing/2021/12/27/why-novavax-stock-is-sinking-today/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1187889461","content_text":"What happened\nShares of Novavax(NASDAQ:NVAX)were sinking 9.6% as of 11:47 a.m. ET on Monday. The company didn't announce any new developments. So what's behind the big decline?\nOther vaccine stocks aren't falling nearly as much. Some were even up a little. That rules out the likelihood that declining concerns about the omicron variant played a major factor behind Novavax's drop.\nInstead, investors are probably growing more anxious about Novavax's planned filing for U.S. Emergency Use Authorization (EUA) of it COVID-19 vaccine NVX-CoV2373. Some investors could also be worried about the quality of Novavax's submission to the Food and Drug Administration (FDA) even if it doesn't experience another delay with the filing.\nCEO Stanley Erck's interview with Yahoo! Finance Live last Thursday likely didn't help reassure investors. When asked about when the FDA filing would be done, Erck replied, \"It's probably going to be next week, but I'm sticking with the claim that we'll be doing this by the end of this year.\"\nSo what\nYet another delay in a U.S. filing for NVX-CoV2373 wouldn't be catastrophic for Novavax as long as the company completes the submission soon in the new year. However, management's credibility would definitely take another big blow.\nBut it's premature at this point to speculate that Novavax won't complete the U.S. EUA filing this week. It's also useless to fret about the quality of the company's FDA package. Novavax recently won European Union authorization for NVX-CoV2373. That shows that the vaccine maker can successfully meet regulators' manufacturing-quality hurdles.\nNow what\nInvestors don't like waiting, but that's exactly what they'll have to do for now with Novavax. The company could complete its EUA filing any day now. It could also pick up new authorizations in other countries where it awaits regulatory decisions.","news_type":1},"isVote":1,"tweetType":1,"viewCount":862,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":46,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/696611114"}